SanReno Therapeutics is a clinical-stage biotech startup founded in December 2021, focusing on kidney diseases and related therapeutic areas. Backed by prominent investors and partners such as Chinook Therapeutics, Pivotal bioVenture Partners China, and Frazier Healthcare Partners, SanReno is dedicated to researching, developing, and commercializing drugs to address crucial medical needs. They hold two core assets, including atrasentan (Phase III) and BION-1301 (Phase II), in the Greater China area and Singapore. The latest funding round in November 2021 secured a noteworthy $40.00M investment from investors such as Frazier Healthcare Partners, Pivotal bioVenture Partners, Versant Ventures, and Samsara BioCapital.
No recent news or press coverage available for SanReno Therapeutics.